Taro Pharma (TARO) Tops Q4 EPS by 24c

Taro Pharma (NYSE: TARO) reported Q4 EPS of $0.54, $0.24 better than the analyst estimate of $0.30. Revenue for the quarter came in at $157.15 million versus the consensus estimate of $154.91 million.

For earnings history and earnings-related data on Taro Pharma (TARO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c